RxDoctor Payments Data

Melanie Durham, NP

Adult Health · Dallas, TXNPI 1730379611

Payments from drug & device makers

$2,315in general payments, 2019–2025

Across 75 payments — averaging $30.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$598
  • Novartis$414
  • Atricure, Inc.$255
  • E.r. Squibb & Sons, L.L.C.$178
  • Paratek Pharmaceuticals, Inc.$165
  • Johnson & Johnson$113
  • plus $591 from 11 others

What the payments were for

  • Consulting fees$80%
  • Food & beverage$2,307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,315 in reported general payments places this provider in the 75th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$94,840
Medicare patients
777
Services billed
1,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,053$1,063,755
XareltoRivaroxaban251$285,933
EntrestoSacubitril/Valsartan44$61,079
MultaqDronedarone Hcl22$45,338
Flecainide Acetate283$15,467
Dofetilide85$13,857
Amiodarone Hcl547$9,418
Metoprolol Succinate266$4,418
Dabigatran EtexilateDabigatran Etexilate Mesylate19$4,083
SotalolSotalol Hcl128$3,438
PradaxaDabigatran Etexilate Mesylate12$2,450
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$1,643
Metoprolol Tartrate186$1,636
Digoxin46$1,331
Midodrine Hcl22$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$92$1,063,7551,053 claims
Johnson & JohnsonXarelto$113$285,933251 claims
NovartisEntresto$414$61,07944 claims
Sanofi-aventis U.S. LLCMultaq$57$45,33822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 933 adult health providers in Texas.

Other adult health in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →